Overall survival benefit and impact on skeletal-related events for radium-223 chloride (Alpharadin) in the treatment of castration-resistant prostate cancer (CRPC) patients with bone metastases: A phase III randomized trial (ALSYMPCA)

被引：0

作者：

Parker, C. ^{[1
]}

Heinrich, D. ^{[2
]}

Helle, S., I ^{[2
]}

O'Sullivan, J. M. ^{[3
]}

Fossa, S. ^{[4
]}

Chodacki, A. ^{[5
]}

Demkow, T. ^{[6
]}

Logue, J. ^{[7
]}

Seke, M. ^{[8
]}

Widmark, A. ^{[9
]}

Johannessen, D. C. ^{[10
]}

Nilsson, S. ^{[11
]}

Hoskin, P. ^{[12
]}

Bottomley, D. ^{[13
]}

Solberg, A. ^{[14
]}

James, N. D. ^{[15
]}

Syndikus, I ^{[16
]}

Wedel, S. A. ^{[17
]}

Kliment, J. ^{[18
]}

Cross, A.

O'Bryan-Tear, C. G. ^{[19
,22
]}

Garcia-Vargas, J. ^{[20
]}

Sartor, O. ^{[21
]}

机构：

[1] Royal Marsden Hosp, Surrey, England

[2] Haukeland Hosp, N-5021 Bergen, Norway

[3] Queens Univ Belfast, Ctr Canc Res & Cell Biol, Belfast, Antrim, North Ireland

[4] Radiumhosp, Oslo, Norway

[5] Hosp Kochova, Chomutov, Czech Republic

[6] Inst Sklodowskiej Curie, Ctr Onkol, Warsaw, Poland

[7] Christie Hosp, Manchester, Lancs, England

[8] Centrallasarettet Vaxjo, Vaxjo, Sweden

[9] Norrlands Univ Hosp, Umea, Sweden

[10] Ullevaal Univ Hosp, Oslo, Norway

[11] Karolinska Univ Sjukhuset, Stockholm, Sweden

[12] Mt Vernon Hosp, Ctr Canc, Middlesex, England

[13] St James Hosp, Leeds LS9 7TF, W Yorkshire, England

[14] St Olavs Hosp, Trondheim, Norway

[15] Inst Canc Studies, Canc Res UK Clin Trials Unit, Birmingham, W Midlands, England

[16] Clatterbridge Ctr Oncol, Wirral, Merseyside, England

[17] Klinikum JW Goethe Univ, Frankfurt, Germany

[18] Martinska Fak Nemocn, Martin, Slovakia

[19] PharmaNet, Hemel Hempstead, England

[20] Bayer HealthCare Pharmaceut, Montville, NJ USA

[21] Tulane Canc Ctr, New Orleans, LA USA

[22] Algeta ASA, Oslo, Norway

来源：

EUROPEAN UROLOGY SUPPLEMENTS | 2012年 / 11卷 / 01期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：E130 / U523

页数：2

共 50 条

[41] Effects of radium-223 dichloride (Ra-223) on health-related quality of life (QOL) outcomes in the phase 3 ALSYMPCA study in patients with castration-resistant prostate cancer (CRPC) and bone metastases
Parker, C.
Heinrich, D.
Bottomley, D.
Hoskin, P.
Franzen, L.
Solberg, A.
Pawar, V.
Reuning-Scherer, J.
O'Bryan-Tear, C. G.
Nilsson, S.
EUROPEAN JOURNAL OF CANCER, 2013, 49 : S689 - S689
[42] Clinical Experience and Radiation Safety of the First-in-Class Alpha-Pharmaceutical, Alpharadin (radium-223) in Patients with Castration-Resistant Prostate Cancer (CRPC) and Bone Metastases
Nilsson, S.
Parker, C.
Biggin, C.
Bruland, O.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2010, 78 (03): : S375 - S376
[43] Further characterization of the effects on sequential treatment of docetaxel before or after radium-223 dichloride therapy in Castration-Resistant Prostate Cancer (CRPC) patients with symptomatic bone metastases included in the phase 3 ALSYMPCA trial
Wedel, S. A.
Mellado, B.
Sartor, O.
Vogelzang, N.
Hoskin, P.
Nilsson, S.
Coleman, R.
Parker, C.
Wahba, M.
Haugen, I
Shore, N.
Oncology Research and Treatment, 2015, 38 : 267 - 267
[44] The impact of genetic mutations on response to radium-223 treatment for castration-resistant prostate cancer with bone metastases.
Liu, Alex John
Kosiorek, Heidi E.
Ueberroth, Benjamin Edward
Kendi, Ayse T.
Tzou, Katherine S.
Quevedo, Fernando
Choo, Richard
Moore, Cassandra N.
Ho, Thai Huu
Singh, Parminder
Keole, Sameer R.
Wong, William
Bryce, Alan Haruo
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[45] ESTIMATING THE ECONOMIC IMPACT OF RADIUM RA 223 DICHLORIDE (RADIUM-223) IN TREATMENT OF CASTRATION-RESISTANT PROSTATE CANCER (CRPC) WITH SYMPTOMATIC BONE METASTASES AND NO KNOWN VISCERAL METASTATIC DISEASE
Valderrama, A.
Bilir, S. P.
Wehler, E. A.
Seal, B. S.
Wen, L.
Yaldo, A.
Munakata, J.
VALUE IN HEALTH, 2014, 17 (03) : A74 - A74
[46] Radium-223 Dichloride: A Novel Treatment Option for Castration-Resistant Prostate Cancer Patients With Symptomatic Bone Metastases
McGann, Shane
Horton, Evan R.
ANNALS OF PHARMACOTHERAPY, 2015, 49 (04) : 469 - 476
[47] External Beam Radiation Therapy (EBRT) Use and Safety With Radium-223 Dichloride (Ra-223) in Patients With Castration-Resistant Prostate Cancer (CRPC) and Symptomatic Bone Metastases (mets) From the ALSYMPCA Trial
Finkelstein, S. E.
Michalski, J. M.
O'Sullivan, J.
Parker, C.
Garcia-Vargas, J.
Sartor, O.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2015, 93 (03): : S201 - S201
[48] Bone-Targeting Radionuclides in the Treatment of Metastatic Castration-Resistant Prostate Cancer: A Review on Radium-223 Chloride (Alpharadin) in Combination with Other Therapies
Alshehri, Ali H. D.
DIAGNOSTICS, 2024, 14 (21)
[49] A phase I/IIa study of the safety and efficacy of radium-223 chloride (Ra-223) with docetaxel (D) for castration-resistant prostate cancer (CRPC) patients with bone metastases.
Morris, Michael J.
Hammers, Hans J.
Sweeney, Christopher
Bloma, Marianne
Aksnes, Anne-Kirsti
O'Bryan-Tear, C. Gillies
Carrasquillo, Jorge A.
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
[50] Phase II Clinical Study of Radium-223 Chloride (BAY 88-8223) in Japanese Patients With Symptomatic Castration-Resistant Prostate Cancer (CRPC) With Bone Metastases
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2016, 14 (04) : 14 - 15

← 1 2 3 4 5 →